abstract |
Manufacture of drugs for the treatment and prevention of patients with diseases associated with apoptotic disorders of T cells, macrophages and / or antigen presenting cells, or treatment of organ rejection in patients who have undergone organ transplantation, particularly solid organ transplantation, and Use of galectin-2, use of a nucleic acid encoding galectin-2, use of its complementary strand, or use of a nucleic acid that hybridizes to the encoding nucleic acid or its complementary strand in the manufacture of a medicament for prevention. |